LaNova Medicines
Latest round
- Series C
Last raised
- Oct 2024
Total raised
- $42M
Investors
- 12
About LaNova Medicines
Based in Shanghai, China, and founded in 2019, LaNova Medicines operates as a pharmaceutical company that focuses on the research and development of clinical-stage innovative drugs. It was recognized as the National High-tech Enterprise. The company's R&D team has an average of more than 15 years of pharmaceutical R&D experience in the fields of immunology and oncology. It cooperated with AstraZeneca, TopAlliance, and other enterprises. The company's LM-302 antibody-drug conjugate project acquired China's NMPA IND approval in 2021. In May 2022, it reached an overseas exclusive licensing cooperation with Turning Point, USA, on the LM-302 project. The company focuses on the research and development of monoclonal anti-tumor drugs that target GPCR and multiple transmembrane proteins. It has an antibody discovery platform, a next-generation ADC technology platform, and an immune bridging multi-specific antibody platform. The targeted antibody discovery platform can screen monoclonal antibodies targeting GPCRs and multiplexed transmembrane proteins. It has multiple product pipelines, including LM-061, LM-102, LM-302, etc. The company generates revenue by providing monoclonal anti-tumor drugs.09% stake in LaNova Medicines at nearly USD 951 million.
Who invested in LaNova Medicines
12 investors across 4 rounds
See all investors in LaNova Medicines
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about LaNova Medicines
Who invested in LaNova Medicines?
LaNova Medicines has 12 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has LaNova Medicines raised?
LaNova Medicines has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did LaNova Medicines last raise money?
LaNova Medicines's most recent round on record is a Series C, in Oct 2024.
What does LaNova Medicines do?
Based in Shanghai, China, and founded in 2019, LaNova Medicines operates as a pharmaceutical company that focuses on the research and development of clinical-stage innovative drugs.
Where is LaNova Medicines headquartered?
LaNova Medicines is headquartered in Shanghai, China.
Which VCs invest in companies like LaNova Medicines?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at LaNova Medicines's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like LaNova Medicines? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.